Charles River Laboratories to acquire gene therapy CDMO Vigene Biosciences
Charles River Laboratories International has signed an all-cash deal worth $292.5 million to acquire Vigene Biosciences, a US-based gene therapy contract development and manufacturing organization ... Read More
HemaCare to be acquired by Charles River Laboratories for $380m
Charles River acquisition of HemaCare : Charles River Laboratories International, an early-stage contract research organization, has agreed to acquire HemaCare for about $380 million in ... Read More